Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Benserazide hydrochloride |
Is a |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Benserazide + levodopa adverse reaction |
Causative agent (attribute) |
False |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Allergy to benserazide and levodopa |
Causative agent (attribute) |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Product containing precisely benserazide 12.5 milligram and levodopa 50 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Benserazide 25 mg and levodopa 100 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Product containing precisely benserazide 50 milligram and levodopa 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Co-beneldopa 12.5mg/50mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Co-beneldopa 25mg/100mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Co-beneldopa 25mg/100mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Product containing benserazide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
1 |
Product containing benserazide and levodopa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Co-beneldopa 25mg/100mg prolonged-release oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Benserazide (substance) |
Inferred relationship |
Some |
|
Allergy to benserazide and levodopa |
Causative agent (attribute) |
False |
Benserazide (substance) |
Inferred relationship |
Some |
1 |
Benserazide hydrochloride |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
|
Benserazide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
1 |
Product containing only benserazide and levodopa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely benserazide 50 milligram and levodopa 200 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely benserazide 50 milligram and levodopa 200 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Benserazide 12.5 mg and levodopa 50 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Benserazide 12.5 mg and levodopa 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Product containing benserazide and levodopa in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Benserazide and levodopa only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely benserazide 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely benserazide 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely benserazide 12.5 milligram and levodopa 50 milligram/1 each conventional release oral capsule (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Product containing precisely benserazide 12.5 milligram and levodopa 50 milligram/1 each conventional release oral capsule (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Benserazide 25 mg and levodopa 100 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |
Benserazide 25 mg and levodopa 100 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Benserazide (substance) |
Inferred relationship |
Some |
2 |